Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Outbreak of an uncommon carbapenemase producing Enterobacteriaceae

ABSTRACT: Outbreak of an uncommon carbapenemase producing Enterobacteriaceae in a digestive rehabilitation center: putative role of Rifaximin

PROVIDER: PRJEB34422 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Carbapenemase-producing Enterobacteriaceae

Project description:Carbapenemase-producing Enterobacteriaceae isolated from Hong Kong, China

| PRJNA595034 | ENA

First dataset - bacterial proteome of carbapanemase-producing Escherichia coli and other Enterobacteriaceae under antibiotic pressure

Project description:Antibiotic resistance associated with the expression of the clinically significant carbapenemases, IMP, KPC, and NDM and OXA-48 in Enterobacteriaceae is emerging as a worldwide calamity to health care. In Australia, IMP-producing Enterobacteriaceae is the most prevalent carbapenemase-producing Enterobacteriaceae (CPE). Genomic characteristics of such carbapenemase-producing Enterobacteriaceae (CPE) are well described, but the corresponding proteome is poorly characterised. We have thus developed a method to analyse dynamic changes in the proteome of CPE under antibiotic pressure. Specifically, we have investigated the effect of meropenem at sub-lethal concentrations to develop a better understanding of how antibiotic pressure leads to resistance. Escherichia coli, producing either NDM, IMP or KPC type carbapenemase were included in this study, and their proteomes were analysed in growth conditions with or without meropenem.

2018-07-11 | PXD008019 | Pride

Enterobacteriaceae Carbapenemase Diversity genome sequencing and assembly

Project description:Enterobacteriaceae Carbapenemase Diversity genome sequencing and assembly

| PRJNA292902 | ENA

Enterobacteriaceae

Project description:Carbapenemase-producing Enterobacteriaceae-isolates from Edo State, Nigeria

| PRJNA382335 | ENA

Enterobacteriaceae

Project description:Whole-Genome Analysis of Carbapenemase-Producing Enterobacteriaceae in Wastewater

| PRJDB6244 | ENA

Carbapenemase Producing Enterobacteriaceae from patients in Qatar

Project description:Whole genome sequencing approach to characterize the antimicrobial resistance genes from ESBL and carbapenemase Producing Enterobacteriaceae in Qatar

| PRJNA656934 | ENA

Enterobacteriaceae

Project description:CREATE-Q: Genomic analysis of carbapenemase-producing Enterobacteriaceae in Queensland

| PRJNA528347 | ENA

Whole transcriptomic analysis of mechanisms of tolerance and resistance to chlorhexidine in carbapenemase-producing Klebsiella pneumoniae clinical strains

Project description:The increasing resistence and/or bacterial tolerance to bactericides, such as chlorhexidine, causes worrisome public health problems. Using transcriptomical and microbiological studies, we analysed the molecular mechanisms associated with the adaptation to chlorhexidine in two carbapenemase-producing strains of Klebsiella pneumoniae belonging ST258-KPC3 and ST846-OXA48.

2020-03-21 | GSE147316 | GEO

Enterobacteriaceae

Project description:Tripoli metallo-beta-lactamase 1 (TMB-1): a novel plasmid-encoded carbapenemase familly in Enterobacteriaceae

| PRJNA473928 | ENA

Carbapenemase-producing Enterobacteriaceae.

Project description:Carbapenemase-producing Enterobacteriaceae (CPE) were almost nonexistent up to the 1990s, but are today encountered routinely in hospitals and other healthcare facilities in many countries including the United States. KPC-producing Klebsiella pneumoniae was the first to emerge and spread globally and is endemic in the United States, Israel, Greece, and Italy. Recently, NDM-producing Enterobacteriaceae and OXA-48-producing K. pneumoniae appear to be disseminating from South Asia and Northern Africa, respectively. They are almost always resistant to all β-lactams including carbapenems and many other classes. Mortality from invasive CPE infections reaches up to 40%. To obtain the maximal benefit from the limited options available, dosing of antimicrobial agents should be optimized based on pharmacokinetic data, especially for colistin and carbapenems. In addition, multiple observational studies have associated combination antimicrobial therapy with lower mortality compared with monotherapy for these infections. The outcomes appear to be especially favorable when patients are treated with a carbapenem and a second agent such as colistin, tigecycline, and gentamicin, but the best approach is yet to be defined.

| S-EPMC4470611 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data